

# Future of Diabetes Research in Europe JDRF Perspective

**IMI-JDRF Diabetes Patient Meeting  
20 May 2014  
Brussels, Belgium**

**Olivier ARNAUD, Pharm D  
JDRF European Research Director  
oarnaud@jdrf.org**

# Future of Diabetes Research: Lessons from Today (1)

---

- Life with T1D is a major daily challenge
- 24 hrs, 7 days, 365 days/year challenge of testing blood sugars, monitoring diet, dosing insulin
- Even with extensive effort, cannot achieve optimal glucose control
- Constant fear of low blood sugars and its accompanying morbidity and mortality
- Risk for long-term diabetic complications, which are devastating in their impact to individuals, families, and society

# Future of Diabetes Research: Lessons from Today (2)

---

- Need to **hear the voice of the patient and patient's family** – deliver impact that addresses daily and long-term needs
- Need **devices and therapies** to decrease the daily burden, uncertainty, danger, and fear of living with T1D or insulin-dependent T2D
- Need to **prevent** low blood sugars and long-term complications
- Need a **Cure**
- Need to **prevent** the disease in **the next generation**
- Need integrated, **high level investment and cooperation in research from all stakeholders** (Member States, Industry, Organization, EC, and Patients)

**J**

**NO T1D**

<b>LESS</b>	Burden
<b>LESS</b>	Invasive
<b>LESS</b>	Complexity
<b>LESS</b>	Danger

**type none**

# JDRF is a virtual R&D organization


- Focused on advancing a pipeline of Research Projects
- Which deliver a continuum flow of therapeutic opportunities



# JDRF Partners with Industry Worldwide

to Translate and Deliver Therapeutic Solutions to Patients

- 57 contracts/collaborative partnerships with 42 companies
- Committed ~\$130M JDRF research funding



## Representative Partners



Genomics Institute of the  
Novartis Research  
Foundation



PHARMACEUTICAL COMPANIES  
OF *Johnson & Johnson*



# JDRF Priority T1D Therapies


Encapsulation



Artificial Pancreas



Smart Insulin



Prevention



Restoration




Complications




# JDRF is a Global Research Organization

## 2013 Research Funding by Country



**U.S. vs Non-U.S.  
2013 Funding**



**Non-U.S.  
2013 Funding**



# JDRF Reinforces Its Effort in Europe

JDRF is a Patient Organization with Key Assets as a Partner in Europe :

## 1 High Level Patient and Public Involvement (PPI)

- **JDRF Board and Board Committees** are individuals and family members affected by T1D
- **Research funding decisions** by Board committee
- **Volunteer-led Online Diabetes Support Team (ODST)**
- **T1D Clinical Trials Connection**  
*Matching people with T1D with appropriate clinical trials*
- **Several tools and supports for people living with T1D:**



**JDRF**  
**typeone**  
nation



# JDRF Reinforces Its Effort in Europe

JDRF is a Patient Organization with Key Assets as a Partner in Europe :

## 1 High Level Patient and Public Involvement (PPI)



### ■ European Affiliates



**March 11<sup>th</sup> 2014** – Over 60 adults and children that live with type 1 diabetes descended on UK Parliament to explain to MPs the impact the condition has on people's lives and encourage increased spending on research

# JDRF Reinforces Its Effort in Europe

JDRF is a Patient Organization with Key Assets as a Partner in Europe :

## 2 Strategy of Active Contribution (Boards – funding - cofunding) in the Development of Initiatives Planned for Horizon 2020 and IMI2

Already participating in IMI / EC supported Programs



# JDRF Reinforces Its Effort in Europe

JDRF is a Patient Organization with Key Assets as a Partner in Europe :

## 3 Further Developing Partnering and Research Support

### Worldwide experience

- Partnering with

**EASD EFSD**

wellcome trust



- Convening high level international **scientific workshops / meetings / symposia** (25 organized in 2013)
- **Management of International Consortia**  
*JDRF Microbiome Consortium, JDRF Immune Memory Consortium, JDRF Biomarker Working Group, JDRF Diabetic Nephropathy Genetics Consortium, JDRF-ITN T1D Preclinical Combination Therapies Consortium, JDRF Resistors and Progressors of Complications Consortium, JDRF nPOD, JDRF nPOD-Viral Working Group, JDRF nPOD-Transplantation Working Group*
- Strong links and collaboration with **NIDDK** international oriented **Special Diabetes Program** (TEDDY, TrialNet)
- **TrialNet** – Funded by NIH and JDRF (funds international sites) for T1D risk screening, natural history, and T1D prevention trials

# JDRF Reinforces Its Effort in Europe

JDRF is a Patient Organization with Key Assets as a Partner in Europe :

4

## Interfacing with Regulatory and Reimbursement Authorities

- Interfacing with US **FDA** (Draft Guidance for Artificial Pancreas Systems, Encapsulation, Stem Cells, Prevention)
- Public consultation to **European Community** for improvement of EC Regulatory Directives  
*(ex of **Medical Devices**, **Clinical trial framework**)*
- Public consultation to **EMA** for improvement of Guidelines  
*Recombinant human insulin and insulin analogues, Insulin Biosimilar specific guidelines, xenografts*
- Addressed **pricing and reimbursement strategy** for Artificial Pancreas medical device market access
- Interfacing with **Government bodies**

## Drive Change in Delivery of Medical Practice

